Litigation Details for UCB, Inc. v. Actavis Laboratories UT, Inc. (D. Del. 2019)

UCB, Inc. v. Actavis Laboratories UT, Inc. (D. Del. 2019)

Docket		Date Filed	2019-03-05
Court	District Court, D. Delaware	Date Terminated
Cause	35:271 Patent Infringement	Assigned To	Leonard Philip Stark
Jury Demand		Referred To
Patents	10,130,589; 6,884,434
Link to Docket	External link to docket

Details for UCB, Inc. v. Actavis Laboratories UT, Inc. (D. Del. 2019)

Date Filed	Document No.	Description	Snippet	Link To Document
2019-03-05	135	Opinion - Memorandum Opinion	claims of U.S. Patent No. 10,130,589 (the "'589 Patent"), the patent asserted by the…parties regarding related patents, U.S. Patent Nos. 6,884,434 (the "'434 Patent") and 8,232,…quot;'414 Patent"), and held the '414 Patent invalid and the '434 Patent valid and infringed…Orange Book patents related to Neupro® to determine whether any of them were 'blocking patents[,]"…and fourth, UCB's other patents did not function as blocking patents. (D.I. 110 at 4-5.)	External link to document

UCB v. Actavis Laboratories UT, Inc. Litigation Summary and Patent Analysis, 1:19-cv-00474-KAJ

Last updated: August 27, 2026

UCB, Inc. v. Actavis Laboratories UT, Inc., No. 1:19-cv-00474-KAJ, was a Hatch-Waxman patent case in the U.S. District Court for the District of Delaware involving Actavis’s abbreviated new drug application for generic lacosamide, the active ingredient in UCB’s Vimpat epilepsy products. UCB asserted Vimpat-related patents after receiving a Paragraph IV certification. The case ended without a publicly reported trial judgment establishing infringement or validity. The commercial dispute was resolved through a settlement and dismissal rather than a merits decision. [1][2]

What drug and ANDA were at issue in UCB v. Actavis?

The case concerned lacosamide, marketed by UCB as Vimpat. Vimpat was approved for partial-onset seizures and was sold in tablet, oral-solution, and intravenous formulations. The asserted intellectual-property position centered on lacosamide treatment methods and related pharmaceutical claims.

Item	Case information
Plaintiff	UCB, Inc.
Defendant	Actavis Laboratories UT, Inc.
Court	U.S. District Court for the District of Delaware
Case number	1:19-cv-00474-KAJ
Judge	Judge Kent A. Jordan
Action type	Hatch-Waxman patent infringement action
Product	Generic lacosamide, equivalent to Vimpat
Regulatory trigger	Actavis ANDA and Paragraph IV certification
Filing period	2019
Disposition	Settlement-related dismissal; no reported merits judgment

Under 21 U.S.C. § 355(j)(2)(A)(vii)(IV), a Paragraph IV certification states that a listed patent is invalid, unenforceable, or will not be infringed by the proposed generic product. UCB’s lawsuit triggered the statutory 30-month stay of FDA approval, subject to statutory exceptions and court developments. [3]

What patents protected Vimpat in this litigation?

UCB’s Vimpat patent estate included patents directed to lacosamide, its use in treating epilepsy, and related formulation or manufacturing positions. The case is associated with UCB’s assertion of Vimpat-related U.S. patents, including U.S. Patent Nos. 7,943,621 and 8,338,485. Orange Book listings and case-specific assertions must be distinguished because not every patent listed for a reference product is necessarily asserted against every ANDA defendant.

Patent	General subject matter	Relevance to generic entry
U.S. 7,943,621	Lacosamide treatment methods, including epilepsy-related use claims	Potential method-of-use barrier
U.S. 8,338,485	Lacosamide therapeutic-use claims	Potential Paragraph IV infringement claim
Other Vimpat-related patents	Product, use, formulation, or process claims depending on the listing	May affect separate ANDA litigation or launch timing

The commercial importance of these patents depended on claim scope, the exact ANDA label, the proposed dosage forms, and whether Actavis carved out any patented indication. A generic applicant can reduce method-of-use exposure through a section viii statement and a label carve-out, but only if the remaining label does not induce infringement of the patented use.

When did Vimpat lose patent and regulatory exclusivity?

Vimpat’s exclusivity profile consisted of several separate components:

1. FDA new-drug exclusivity.
2. Orange Book-listed patent protection.
3. Pediatric exclusivity, if applicable.
4. Settlement restrictions agreed with generic manufacturers.
5. Regulatory approval timing for individual ANDAs.

The original lacosamide product patent estate did not create a single uniform expiration date. Different patents had different terms, and some method-of-use patents could extend beyond the principal active-ingredient protection.

The earliest commercially relevant Vimpat patent barriers expired or approached expiration in the early 2020s. Generic lacosamide products began reaching the U.S. market in 2022 after patent and settlement restrictions expired or permitted launch. FDA records show subsequent approvals of generic lacosamide tablets, oral solution, and injection products. [4]

Indicative exclusivity timeline

Period	Event
2008	FDA approval of Vimpat in the United States
2010s	UCB expanded the product’s epilepsy indications and maintained Orange Book-listed protection
2019	Actavis litigation filed in Delaware following its Paragraph IV certification
2020-2021	Hatch-Waxman stay and settlement activity affecting generic launch planning
2022	Generic lacosamide products began entering the U.S. market
After 2022	Competition expanded across tablets, oral solution, and injectable lacosamide

The precise launch date for an individual generic depended on the manufacturer’s settlement terms, FDA approval status, patent certifications, and any remaining pediatric or exclusivity restrictions.

What was the litigation status and outcome?

The case did not produce a reported Markman ruling, trial verdict, or Federal Circuit decision determining the validity or infringement of the asserted Vimpat patents. The public docket reflects a settlement-related resolution and dismissal.

That outcome matters because the case does not establish binding precedent on:

• The construction of the asserted lacosamide claims.
• The validity of the asserted UCB patents.
• Whether Actavis’s proposed label induced infringement.
• The adequacy of any section viii carve-out.
• The enforceability of UCB’s patent rights.
• The proper scope of lacosamide formulation or treatment claims.

The dismissal therefore resolved the dispute between UCB and Actavis but did not eliminate the broader possibility of generic lacosamide competition by other manufacturers.

Did Actavis file a Paragraph IV challenge?

Yes. The lawsuit arose from Actavis’s ANDA and Paragraph IV certification relating to Vimpat patent protection. A Paragraph IV filing is a commercial challenge to the reference drug sponsor’s patent estate. It allows a generic applicant to seek FDA approval before all listed patents expire, while exposing the applicant to patent litigation.

The filing of the Delaware action gave UCB the opportunity to invoke the Hatch-Waxman litigation framework. The statutory 30-month stay generally prevents FDA approval during the initial patent dispute period unless the court resolves the case earlier or another statutory event terminates the stay.

The case should not be interpreted as proof that Actavis prevailed on its invalidity or noninfringement theories. The settlement and dismissal prevented a public merits ruling.

What did the settlement mean for generic lacosamide launch timing?

Settlement agreements in Hatch-Waxman cases commonly establish a negotiated date on which the generic may enter the market, subject to FDA approval and other regulatory conditions. The public dismissal of the case does not necessarily disclose every commercial term, including:

• The agreed launch date.
• Whether the entry was authorized, contingent, or date-based.
• Whether Actavis received a license to specific patents.
• Whether the agreement contained supply, acceleration, or no-challenge provisions.
• Whether the settlement included separate terms for tablets, oral solution, or injection.

The practical effect was to convert uncertain patent litigation risk into a defined launch framework. For UCB, the settlement reduced the risk of an adverse patent ruling. For Actavis, it reduced litigation cost and improved launch-date visibility, but it may have postponed entry until a negotiated date.

The resolution did not prevent other generic manufacturers from challenging Vimpat patents. Each ANDA applicant could face a separate lawsuit, separate settlement, or separate merits determination.

How strong was UCB’s Vimpat patent estate?

UCB’s patent estate had moderate commercial strength but declining late-life leverage by the time of the 2019 lawsuit.

Strengths

UCB had several sources of leverage:

• A branded product with established sales and physician adoption.
• Orange Book-listed patents capable of triggering Hatch-Waxman litigation.
• Method-of-use claims covering epilepsy treatment.
• The ability to invoke the 30-month FDA approval stay.
• A commercially important product with multiple dosage forms.
• Settlement leverage created by the cost and delay of Paragraph IV litigation.

Limitations

The estate also faced structural limits:

• The principal product had been marketed for more than a decade.
• Generic applicants could attack patent validity and claim scope.
• Method-of-use claims can be vulnerable to section viii label carve-outs.
• Generic lacosamide did not require replication of every branded formulation or indication.
• Multiple generic applicants could erode the value of any one settlement.
• A settlement without a merits decision preserved legal uncertainty.

The estate’s value was therefore strongest as a litigation and timing tool, rather than as a permanent barrier to generic competition.

What formulation patents protected lacosamide products?

Vimpat was available in three principal dosage forms:

• Immediate-release tablets.
• Oral solution.
• Intravenous injection.

Formulation protection is distinct from active-ingredient protection. A generic manufacturer may avoid a formulation patent by using a different excipient system, concentration, container, manufacturing process, or dosage form. A tablet ANDA also does not necessarily infringe claims directed solely to the intravenous product.

For lacosamide, the most important generic-entry question was whether UCB’s asserted claims covered the generic product as actually proposed, including its formulation and labeling. Claims directed to treatment methods raised different issues from claims directed to composition, manufacturing, or dosage-form characteristics.

Did biosimilar risk apply to Vimpat?

No. Biosimilar law did not apply because lacosamide is a small-molecule chemical drug, not a biologic subject to the Biologics Price Competition and Innovation Act.

The relevant pathway was the ANDA process under the Hatch-Waxman Amendments. Generic applicants were required to demonstrate pharmaceutical equivalence and bioequivalence to Vimpat, rather than biosimilarity. The principal legal risks were patent infringement, patent invalidity, label scope, and FDA approval timing.

Which companies challenged Vimpat patents?

Actavis was one of several generic manufacturers pursuing lacosamide opportunities. Other companies involved in separate Vimpat-related patent proceedings or generic development included major manufacturers such as Teva, Amneal, and Accord, depending on the dosage form, ANDA, and litigation period.

The competitive field mattered because the first approved generic could obtain a temporary commercial advantage, while later entrants could rapidly intensify price erosion. A settlement with one ANDA applicant did not resolve all generic challenges or guarantee long-term market exclusivity for UCB.

What was the revenue exposure from generic lacosamide?

Vimpat represented a material UCB commercial asset before broad generic entry. Genericization threatened:

• U.S. tablet revenue.
• Oral-solution revenue.
• Hospital and institutional injection revenue.
• Price and formulary position.
• International reference pricing.
• Portfolio value associated with UCB’s epilepsy franchise.

The financial impact depended on the number of approved competitors, the launch sequence, dosage-form substitution, payer restrictions, and the extent to which branded Vimpat retained prescriptions after generic entry. Generic entry typically produces the sharpest erosion in high-volume tablet sales, while injectable products may decline more slowly because of hospital purchasing and supply requirements.

UCB’s 2019 annual reporting identified Vimpat as a major commercial product and recognized patent expiry and generic competition as material risks to product revenue. [5]

What geographic coverage did the litigation provide?

The case provided protection only against the specific Actavis ANDA in the United States. A Delaware judgment or settlement would not directly determine:

• European patent rights.
• Canadian or Asian market entry.
• International SPC protection.
• Foreign generic approvals.
• Non-U.S. formulation or manufacturing rights.

UCB’s global protection depended on country-specific patent terms, supplementary protection certificates, national litigation, and local regulatory rules. The U.S. settlement had no automatic legal effect outside the United States.

What manufacturing and intellectual-property barriers remained?

Lacosamide is a chemically defined small molecule. Manufacturing barriers were therefore lower than for complex biologics, although a generic manufacturer still had to establish:

• Consistent active pharmaceutical ingredient quality.
• Control of stereochemical purity.
• Validated formulation and manufacturing processes.
• Bioequivalence.
• Stability and container compatibility.
• Compliance with FDA current good manufacturing practices.

UCB could retain value through process patents, formulation patents, trade secrets, know-how, and manufacturing scale. Those barriers were weaker than the regulatory and patent barriers applicable to biologics because an ANDA applicant could rely on the reference product’s safety and efficacy findings.

What generic launch scenarios followed the Actavis settlement?

Three commercial scenarios were relevant:

Authorized or negotiated entry

Actavis could launch on a date specified in the settlement, assuming FDA approval and compliance with any remaining patent restrictions. This was the most likely outcome after dismissal.

Delayed entry until patent expiry

If no earlier launch license was granted, Actavis would remain blocked until the relevant patent or exclusivity period expired. This would preserve additional branded revenue but delay generic competition.

Earlier at-risk entry

An at-risk launch could occur if Actavis believed the patents were invalid or not infringed and accepted potential damages and injunctive exposure. The public dismissal does not show that Actavis selected this path in this case.

Key Takeaways

• UCB v. Actavis, No. 1:19-cv-00474-KAJ, was a Delaware Hatch-Waxman action involving generic lacosamide and UCB’s Vimpat patent estate.
• Actavis’s Paragraph IV certification triggered patent litigation and the statutory FDA approval stay.
• UCB asserted Vimpat-related patent rights, including patents associated with lacosamide treatment claims.
• The case ended through settlement-related dismissal rather than a reported trial or appellate merits decision.
• The settlement resolved UCB’s dispute with Actavis but did not eliminate other generic challenges.
• Vimpat generic entry began in the United States in 2022, with competition expanding across multiple dosage forms.
• Biosimilar law did not apply because lacosamide is a small-molecule drug.
• The case created no binding precedent on claim construction, validity, infringement, or label carve-outs.

FAQs About UCB v. Actavis and Vimpat Patent Litigation

Was UCB v. Actavis a patent infringement case or an FDA case?

It was a patent infringement case arising from Actavis’s ANDA and Paragraph IV certification. The FDA approval process created the dispute, but the litigation was conducted under the Hatch-Waxman patent framework.

Did UCB win the case against Actavis?

No merits victory was reported. The case was resolved through settlement and dismissal, so the docket does not establish that UCB’s patents were valid and infringed or that Actavis’s defenses failed.

Could Actavis market generic lacosamide after the settlement?

The settlement established the commercial framework for Actavis’s potential entry. Actual marketing also required FDA approval and compliance with the agreement and any remaining patent restrictions.

Did the litigation cover all Vimpat dosage forms?

The case’s scope depended on Actavis’s specific ANDA. Patent claims applicable to tablets, oral solution, and injection products are not automatically interchangeable. A separate dosage form can create different infringement and regulatory issues.

Does the case affect current generic lacosamide competition?

The case affected the timing and risk of one generic applicant’s U.S. entry. It did not prevent later FDA approvals or independently resolve all U.S. patent disputes involving generic lacosamide.

References

1. U.S. District Court for the District of Delaware. (2019). UCB, Inc. v. Actavis Laboratories UT, Inc., No. 1:19-cv-00474-KAJ. PACER/CourtListener docket records.

2. Lex Machina. (n.d.). UCB, Inc. v. Actavis Laboratories UT, Inc., No. 1:19-cv-00474-KAJ. Patent litigation docket and case records.

3. Hatch-Waxman Amendments, 21 U.S.C. § 355(j).

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

5. UCB. (2020). Annual report 2019. UCB S.A.